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Summary
Background.  —  Percutaneous  mitral  valve  repair  (MVR)  using  the  MitraClip® is  a  new  option  for
severe mitral  regurgitation  (MR).
Aim.  —  To  describe  initial  French  experience  regarding  short-term  and  mid-term  safety  and
efﬁcacy.
Methods. —  A  multicentre  cohort  reported  experience  of  percutaneous  MVR  using  the  MitraClip®
in  French  centres  from  December  2010  to  September  2012.  All  patients  were  judged  inoperable
or at  high  surgical  risk.  Short-term  and  mid-term  safety  and  efﬁcacy  results  are  presented.
Results. —  Sixty-two  patients  (72.7  ±  11.4  years;  71.7%  men;  81.0%  New  York  Heart  Association
[NYHA] class  III  or  IV;  logistic  Euroscore  18.7  ±  13.1%;  93.3%  MR  ≥  grade  3;  73.8%  secondary
MR) underwent  percutaneous  MVR  using  the  MitraClip® under  general  anaesthesia.  Proce-
dural success  was  95.2%  (83.1%  of  patients  received  one  clip;  16.9%  received  two  clips).  At
discharge, 88.2%  of  implanted  patients  had  a  residual  MR  ≤  grade  2.  Transthoracic  echocardi-
ography showed  a  signiﬁcant  decrease  in  ejection  fraction  (39.9  ±  14.8%  pre  vs.  36.2  ±  14.3%
post), end-diastolic  diameter  (63.8  ±  10.6  mm  vs.  61.4  ±  12.3  mm,  respectively)  and  systolic
pulmonary  pressure  (52.1  ±  13.9  mmHg  vs.  44.7  ±  10.9  mmHg,  respectively).  The  in-hospital
mortality rate  was  3.2%.  The  survival  rate  at  6-month  follow-up  was  estimated  at  83.1%,  with
90.9% of  patients  in  NYHA  class  I  or  II  and  residual  MR  ≤  grade  2  in  80%  of  cases.
Conclusion.  —  This  initial  French  experience,  despite  being  in  its  learning  phase,  showed  promis-
ing results  in  patients  considered  ineligible  for  surgery,  as  observed  in  more  experienced
centres. Randomized  studies  are  mandatory  to  conﬁrm  these  preliminary  data.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  réparation  percutanée  de  la  valve  mitrale  par  le  système  MITRACLIP  est  une
nouvelle  option  thérapeutique  dans  la  prise  en  charge  de  la  régurgitation  mitrale  sévère.
Objectifs.  —  Cet  article  décrit  l’expérience  initiale  du  traitement  percutané  des  IM  sévères  par
le système  « MitraClip  » en  France  en  termes  d’efﬁcacité  et  de  tolérance.
Méthodes.  —  Cette  étude  multicentrique  rapporte  l’expérience  des  centres  franc¸ais  sur
l’ensemble  des  procédures  MitraClip® de  décembre  2010  à  septembre  2012.  Tous  les  patients
étaient jugés  non  éligibles  ou  à  haut  risque  pour  la  chirurgie.
Résultats.  —  Soixante-deux  patients  (72,7  ±  11,4  ans  ;  71,7  %  de  sexe  masculin  ;  81,0  %  de  classe
NYHA III  ou  IV  ;  logistic  Euroscore  :  18,7  ±  13,1  %  ;  93,3  %  d’IM  de  grade  3  ou  plus  ;  73,8  %  d’IM  sec-
ondaire) ont  bénéﬁcié  d’une  procédure  MitraClip  sous-anesthésie  générale.  Le  taux  de  succès  de
procédure  était  de  95,2  %  (83,1  %  des  patients  recevaient  un  clip  et  16,9  %  en  recevaient  deux).
À la  sortie  de  l’hôpital,  88,2  %  des  patients  implantés  avaient  une  IM  résiduelle  inférieure  ou
égale à  2.  Les  données  d’échographie  transthoracique  ont  rapporté  une  diminution  signiﬁcative
de la  fraction  d’éjection  (39,9  ±  14,8  %  pre  vs  36,2  ±  14,3  %  post),  du  diamètre  télédiastolique
(63,8 ±  10,6  mm  vs  61,4  ±  12,3  mm,  respectivement)  et  de  la  pression  pulmonaire  systolique
(52,1 ±  13,9  mmHg  vs  44,7  ±  10,9  mmHg,  respectivement).  La  mortalité  intra-hospitalière  était
de 3,2  %.  La  survie  à  six  mois  post-procédure  était  estimée  à  83,1  %  avec  90,9  %  des  patients  en
classe NYHA  de  I  ou  II  et  80  %  avec  une  IM  résiduelle  inférieure  ou  égale  à  2.
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Conclusion.  —  Cette  expérience  initiale,  bien  que  dans  sa  phase  d’apprentissage,  rapporte,  à
l’instar de  centres  expérimentés,  des  résultats  prometteurs  chez  des  patients  non  éligibles
à la  chirurgie.  Des  essais  randomisés  contrôlés  sont  nécessaires  pour  conﬁrmer  ces  résultats
préliminaires.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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AIntroduction
The  recent  revolution  with  transcatheter  aortic  valve
implantation  (TAVI)  procedures  has  opened  and  stimu-
lated  the  road  to  using  the  percutaneous  approach  for
other  valves.  Different  devices  for  the  mitral  valve  have
been  tested  in  patients  [1].  Most  were  stopped  after
disappointing  initial  experiences,  some  are  in  the  early
phase  of  development  and  only  one  —  the  MitraClip®
system  (Abbott  Vascular,  Santa  Clara,  CA,  USA)  —  is
in  current  commercial  development  (more  than  6000
patients  implanted  worldwide),  with  encouraging  results
[2—4].
The  objective  of  this  paper  is  to  describe  initial  French
experience  (seven  centres)  of  feasibility,  safety  and  efﬁ-
cacy  and  to  discuss  perspectives  from  growing  worldwide
experience.
Materials and methods
Study design and patient selection
This  multicentre  cohort  study  selected  all  patients  who
underwent  a  MitraClip  procedure  in  France  from  December
2010  to  September  2012.
All  patients  were  judged  inoperable  or  at  high  surgi-
cal  risk  by  a  heart  team  that  included  an  interventional
cardiologist,  a  cardiac  surgeon,  an  echocardiographer  and
an  anaesthesiologist.  Procedure  outcomes  for  all  patients
from  seven  French  centres  (Lyon,  Montpellier,  Nantes,  Paris-
Bichat,  Paris-Massy,  Rennes  and  Toulouse)  were  reported  to
a  database.  All  centres  had  long-term  experience  of  trans-
septal  catheterization  and  were  authorized  to  perform  TAVI
according  to  French  legislation.  Data  were  collected  anony-
mously  from  medical  charts  in  each  centre  using  a  speciﬁc
case  report  form  and  were  recorded  in  a  registry.  The  site
reported  events  and  changes  in  left  ventricle  function  and
mitral  regurgitation  (MR).
Description of procedure
All  procedures  were  performed  with  proctoring  from
Abbott  Vascular,  including  help  in  the  selection  of  the
patients  (based  on  echocardiographic  criteria  as  men-
tioned  in  the  EVEREST  programme),  and  the  presence  of
two  technician  specialists  during  all  the  procedures.  All
implantations  were  performed  in  a  catheterization  lab-
oratory  or  hybrid  rooms  under  general  anaesthesia.  The
medical  team  involved  two  interventional  cardiologists  or
one  interventional  cardiologist  plus  one  cardiac  surgeon,
w
t
1ne  echocardiographer  trained  for  the  procedure  and  one
naesthesiologist.  Fluoroscopy  and  three-dimensional  tran-
oesophageal  echocardiography  were  systematically  used
hroughout  the  procedure  as  previously  described  in  the
VEREST  II  trial  [2].
ndpoints
he  feasibility  of  the  MitraClip  procedure  was  assessed  by
he  proportion  of  successful  clip  implantations,  correspond-
ng  to  patients  in  whom  a  clip  implantation  was  achieved.
Procedures  were  also  described  by  the  number  of  clips
mplanted  per  patient  as  well  as  by  the  mean  duration  of
he  procedure,  corresponding  to  the  duration  from  venous
uncture  to  complete  ablation  of  the  implantation  material.
Safety  was  evaluated  and  described  by  the  occurrence  of
n-hospital  deaths,  in-hospital  surgical  mitral  valve  repairs
MVR)  and  other  non-fatal  adverse  events,  as  well  as  by  the
roportion  of  per  procedural  blood  transfusions.  In-hospital
vents  corresponded  to  events  occurring  during  the  hospital
tay  for  the  MitraClip  procedure.  The  6-month  survival  rate
as  also  estimated.
Efﬁcacy  was  assessed  by  the  proportion  of  implanted
atients  with  a  residual  MR  ≤  grade  2  at  discharge  and  at
 months,  as  well  as  by  the  distribution  of  patients  according
o  New  York  Heart  Association  (NYHA)  class  before  procedure
nd  at  6  months.  Furthermore,  the  impact  of  the  MitraClip
n  echocardiographic  variables  was  evaluated,  taking  into
ccount  systolic  pulmonary  artery  pressure  (PAPs),  left  ven-
ricular  end-diastolic  diameter,  left  ventricular  end-systolic
iameter,  ejection  fraction,  mean  mitral  gradient,  veloc-
ty  time-integral  left  ventricular  outﬂow  tract  (VTI  LVOT)
nd  VTI  mitral  inﬂow.  MR  severity  was  quantiﬁed  according
o  the  American  Society  of  Echocardiography  guidelines  [5].
nterpretation  of  echocardiographic  examinations  from  each
atient  in  the  registry  was  not  centralized.
tatistical analysis
uantitative  variables  are  presented  as  mean  ±  standard
eviation  and  were  compared  by  using  the  paired  Student’s
 test  or  the  Wilcoxon  signed  rank  test,  depending  on  their
ormality,  which  was  assessed  by  the  Kolmogorov-Smirnov
est.  Ordinal  variables  are  presented  as  counts  and  percent-
ges  and  were  compared  by  using  the  Wilcoxon  signed  rank
est.  For  each  variable,  analysis  was  only  performed  on  cases
ith  matched  data  (i.e.  excluding  cases  with  missing  data).
 level  of  0.05  was  used  to  test  for  signiﬁcance.  Survival
as  calculated  with  the  use  of  Kaplan-Meier  analysis.  Sta-
istical  analysis  was  performed  using  SPSS  software,  version
9.0  (IBM  Corp.,  Armonk,  NY,  USA).
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Table  1  Patient  characteristics  at  baseline  (n  =  62).
Variable
Age  (years)  72.7  ±  11.4
Age  >  65  years  79
Men  71.7
Permanent  pacemaker  or
implantable  automatic
deﬁbrillator
41.9
Previous  cardiovascular  surgery  30.6
Previous  percutaneous  coronary
intervention
27.4
History  of  coronary  artery  disease  57.4
Number  of  hospitalizations  for  CHF
(<  12  months)
2.5 ±  2.6
Logistic  Euroscore  (%)  18.7  ±  13.1
NYHA  class  III  or  IV  81.0
MR  severity  at  rest  ≥  grade  3  93.3
MR  etiology
Primary  23.0
Secondary  73.8
Mixed  3.2
Data are mean ± standard deviation or percentage. CHF: con-
gestive heart failure; MR: mitral regurgitation; NYHA: New York
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esults
atient characteristics
rom  December  2010  to  September  2012,  62  patients  (71.7%
en;  73.8%  with  secondary  MR)  underwent  a  percutaneous
VR  using  the  MitraClip  device;  their  demographic  charac-
eristics  are  presented  in  Table  1.
The  number  of  MitraClip  procedures  performed  in  each
entre  varied  between  two  and  18  (Paris-Bichat:  n  =  18;
yon:  n  =  13;  Nantes:  n  =  9;  Toulouse:  n  =  9;  Paris-Massy:
 =  7;  Montpellier:  n  =  4;  Rennes:  n  =  2).  The  mean  logistic
uroscore  was  18.7  ±  13.1%.  The  mean  number  of  hospi-
alizations  for  congestive  heart  failure  in  the  12  months
M
c
t
g
Table  2  Transthoracic  echocardiographic  variables  before  pro
Echocardiographic  variable  Mean  ±  standard  deviation  
Baseline  At  disch
MR  severity  grade  3.5  ±  0.5  1.6  ±  0
VTI  LVOT  (cm)  15.1  ±  4.1  16.8  ±  7
VTI  mitral  inﬂow  (cm)  23.8  ±  6.2  31.2  ±  1
Mean  gradient  (mmHg)  2.1  ±  1.3  3.1  ±  1
EF  (%)  39.9  ±  14.8  36.2  ±  1
LVEDD  (mm)  63.8  ±  10.6  61.4  ±  1
LVESD  (mm)  47.8  ±  13.7  48.2  ±  1
PAPs  (mmHg) 52.1  ±  13.9  44.7  ±  1
LA  diameter  (mm)  50.8  ±  9.5  50.1  ±  6
EF: ejection fraction; LA: left atrium; LVEDD: left ventricular end-diast
mitral regurgitation; PAPs: systolic pulmonary artery pressure; VTI LVOX.  Armoiry  et  al.
efore  the  procedure  was  2.5  ±  2.6  per  patient  (range,
—12)  despite  optimal  medical  treatment.
rocedural characteristics
he  implantation  started  with  a  venous  femoral  access  and
 trans-septal  puncture  under  ﬂuoroscopy,  plus  two-  and
hree-dimensional  transoesophageal  echocardiography.  The
lip  delivery  system  was  then  introduced  into  the  left  atrium
nd  the  clip  was  positioned  in  the  middle  of  the  regurgitant
et  where  the  two  leaﬂets  were  grasped.  After  assessment  of
he  regurgitation  decrease,  the  decision  to  deliver  or  repo-
ition  the  clip  was  taken.  A  second  clip  implantation  was
ossible  in  case  of  unsatisfactory  control  of  regurgitation.
Successful  clip  implantation  was  obtained  in  95.2%  of
ases  (95.5%  for  secondary  MR;  92.8%  for  primary  MR).  One
lip  was  implanted  in  83.1%  of  cases  and  two  clips  in  16.9%
f  cases.  The  MR  aetiologies  in  the  patients  who  had  two
lips  implanted  were  mainly  functional  (90%  secondary  MR
s.  10%  primary  MR).  The  three  failed  clip  implantations,
hich  occurred  in  two  patients  with  primary  MR  (67%)  and
ne  with  secondary  MR  (33%),  corresponded  to  a  challenging
natomy.
The  mean  duration  of  the  procedure  was  192  ±  87  min
range,  72—510  min).  Inotropic  agents  were  used  during  the
rocedure  in  28.6%  of  cases.
Postimplantation  thromboprophylaxis  included  clopido-
rel  for  3—6  months  and  low  dose  aspirin  indeﬁnitely.  When
itamin  K  antagonists  were  needed  (mainly  for  concomitant
trial  ﬁbrillation),  the  anticoagulation  regimen  combined  a
itamin  K  antagonist  with  aspirin.
The  mean  duration  of  hospital  stay  was  10.9  ±  8.8  days
range,  4—43  days;  median,  8  days).
afety variables
n-hospital  death  occurred  in  two  patients  with  secondary
R  (3.2%):  one  on  day  11  secondary  to  oesophagus  compli-
ation  and  one  on  day  4  in  a  patient  who  required  conversion
o  surgery,  indicated  for  severe  increased  MR  due  to  multiple
rasping  attempts  during  the  MitraClip  procedure.
cedure  and  at  discharge.
Cases  with  matched  data  (n)  P
arge
.8  53  1.10−9
.1  25  0.13
3.3  23  0.024
.7  26  0.002
4.3  49  0.0004
2.3  45  0.014
4.2  40  0.68
0.9  40  0.0001
.8  16  0.6
olic diameter; LVESD: left ventricular end-systolic diameter; MR:
T: velocity time-integral left ventricular outﬂow tract.
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Figure 2. New York Heart Association (NYHA) class before mitral
v
n
1
m
o
i
t
2
f
were  not  modiﬁed  because  the  number  of  observations  was
limited  (Table  4).Figure 1. Kaplan—Meier survival curve for the MitraClip French
cohort.
Two  other  surgical  MVRs  were  required  after  the  Mitra-
Clip  procedure  (patients  with  secondary  MR):  one  secondary
to  a  clip  partial  detachment  and  one  on  day  11  because  of
a  secondary  mitral  valve  tear  beside  the  clip.  No  further
complications  occurred  in  these  two  patients.
Other  non-fatal  adverse  events  were  observed  in  seven
patients  (11.3%).  One  clip  was  implanted  in  the  wrong
position  in  the  subvalvular  apparatus,  where  it  had  been
trapped  during  the  intraventricular  manoeuvres.  No  addi-
tional  clip  was  implanted  and  this  patient  had  an  uneventful
follow-up  despite  the  persistence  of  non-modiﬁed  MR.  Other
in-hospital  events  were:  one  deep  venous  thrombosis;  one
bleeding  at  puncture  site;  one  new-onset  atrial  arrhythmia;
one  acute  febrile  respiratory  illness;  one  false  aneurysm  at
venous  puncture  site;  and  one  tamponade  on  day  6  treated
by  percutaneous  drainage.
Per  procedural  blood  transfusion  was  necessary  in  ﬁve
patients  (8.1%);  in  these  cases,  the  mean  number  of  packed
red  blood  cells  received  per  patient  was  3.0  ±  2.2.
No  cases  of  stroke  or  myocardial  infarction  were
reported.
Efﬁcacy variables at discharge and at 6-month
follow-up
At  discharge,  the  proportion  of  implanted  patients  with
residual  MR  ≤  grade  2  was  88.2%.
Echocardiographic  data  showed  that  MR  severity  grade,
PAPs  and  left  ventricular  end-diastolic  diameter  were
reduced  before  and  after  clip  implantation  (Table  2).  VTI
mitral  inﬂow  and  mitral  gradient  were  increased  before  and
after  the  procedure.  There  was  no  signiﬁcant  change  in
left  ventricular  end-systolic  diameter.  Consequently,  ejec-
tion  fraction  decreased  from  39.9  ±  14.8%  to  36.2  ±  14.3%
(P  =  0.0004).
Short-term  safety  and  efﬁcacy  outcomes  depending  on
MR  aetiology  are  summarized  in  Table  3.
F
r
dalve repair and at 6-month follow-up. Cases with matched data:
 = 22.
Mean  and  median  follow-up  durations  were  195  and
41  days,  respectively  (range,  8—706  days).
A  Kaplan-Meier  survival  curve  is  shown  on  Fig.  1.  At  6-
onth  follow-up,  estimated  survival  was  83.1%,  with  90.9%
f  patients  in  NYHA  class  I  or  II  vs.  22.7%  before  MitraClip
mplantation  (Fig.  2).  MR  correction  was  maintained  over
ime,  with  12/15  patients  (80%)  with  residual  MR  ≤  grade
 (Fig.  3).  Interestingly,  PAPs  was  signiﬁcantly  reduced
rom  57.1  ±  19.2  mmHg  to  45.8  ±  9.5  mmHg.  Other  variablesigure 3. Mitral regurgitation grade severity before mitral valve
epair, at discharge and at 6-month follow-up. Cases with matched
ata: n = 15.
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Table  3  Short-term  safety  and  efﬁcacy  outcomes  depending  on  mitral  regurgitation  etiologya.
Variable  Primary  MR
(n  =  14)
Secondary  MR
(n  =  45)
Mean  age  (years)  82.4  ±  5.7  69.8  ±  11.5
History  of  coronary  artery  disease  17  67
Logistic  Euroscore  (%) 16.3 ±  10.2 19.4  ±  14.2
NYHA  class  III  or  IV 79  84
Successful  clip  implantation 92.8  95.5
In-hospital  mortality  0  4.4
Post  MitraClip  procedure  mitral  surgery  7.1  2.2
Non-fatal  in-hospital  adverse  events  7.1  13.3
MR  at  baseline  (≤  grade  2/>  grade  2)  9/91  0/100
MR  at  discharge  (≤  grade  2/>  grade  2)  75/25  91/9
Data are mean ± standard deviation or percentage. NYHA: New York Heart Association; MR: mitral regurgitation.
a The mixed etiologies are not presented in the table.
w
f
D
T
a
h
d
w
i
i
s
e
t
o
E
M
7
E
e
[
o
m
f
G
p
r
l
s
t
q
t
m
h
q
w
m
t
MIn  implanted  patients  for  whom  6-month  follow-up  visit
as  documented  (n  =  24),  no  further  surgery  had  been  per-
ormed.
iscussion
he  French  centres  that  participated  in  this  registry  were
lready  involved  in  the  TAVI  programme,  with  a  structured
eart  team  already  used  to  performing  accurate  and  multi-
isciplinary  patient  selection.
Encouraging  results  were  seen  in  primary  MR  (Table  3)
hen  the  mitral  valve  prolapse  was  localized,  ideally  on  P2,
n  a  place  where  there  are  no  chordae  disturbing  the  clip
mplantation.  This  indication  might  be  a  good  option  when
urgery  is  contraindicated  or  carries  a  very  high  risk.
One  of  the  major  evolutions  with  the  MitraClip  experi-
nce  since  the  EVEREST  II  study  publication  [2]  has  been
he  shift  in  the  indications,  which  were  originally  mainly
rganic  (73%  of  primary  MR  vs.  23%  of  secondary  MR  in  EVER-
ST  II)  and  are  now  mainly  functional  (80%  of  secondary
R  in  the  Euroaccess  Registry).  In  this  series,  the  ratio  of
4%  secondary  MR  corresponds  to  the  current  indications  in
urope.
The  MitraClip  procedure  is  demanding,  so  the  French
xperience  reported  here  is  still  within  the  learning  curve
o
f
a
Table  4  Echocardiographic  variables  before  mitral  valve  repa
Echocardiographic  variable  Mean  ±  standard  deviation  
Baseline  At  6  months  p
EF  (%)  39.7  ±  15.4  39.7  ±  16.6  
LVEDD  (mm)  62.4  ±  8.7  61.6  ±  11.9  
LVESD  (mm)  48.0  ±  13.2  47.2  ±  15.7  
PAPs  (mmHg)  57.1  ±  19.2  45.8  ±  9.5  
EF: ejection fraction; LVEDD: left ventricular end-diastolic diamete
pulmonary artery pressure.
a Variables are only presented for matched data of ≥ 10 cases.6].  Thanks  to  an  efﬁcient  proctoring  support,  the  results
f  this  initial  experience  are  similar  to  those  reported  by
ore  experienced  teams  in  terms  of  proportions  of  success-
ul  clip  implantation  (95%  in  the  French  cohort  vs.  98%  in  the
erman  TRAMI  registry  [7]).
Procedure  safety  has  been  conﬁrmed  in  this  cohort,  as
reviously  described,  and  our  results  are  similar  to  those
eported  in  other  recent  publications  [8,9], despite  the
imited  experience  of  the  centres.
The  efﬁcacy  of  the  MitraClip  procedure  in  reducing  MR
everity  grade  has  also  been  observed,  with  the  limita-
ions  of  quantiﬁcation  of  MR  after  clip  implantation.  Indeed,
uantiﬁcation  of  severity  of  MR  after  MitraClip  implanta-
ion  may  be  challenging  due  to  the  presence  of  a  double
itral  oriﬁce  and  multiple  jets.  However,  previous  studies
ave  shown  that  the  use  of  a  combination  of  qualitative  and
uantitative  variables  (colour  ﬂow  grade,  vena  contracta
idth,  regurgitant  oriﬁce  area,  regurgitant  volume  and  pul-
onary  vein  ﬂow  pattern)  in  a  systematic  protocol  may  allow
reatment  efﬁcacy  after  clip  repair  [10].
Finally,  clinical  beneﬁt  was  achieved  in  patients  in  whom
R  severity  was  corrected,  as  illustrated  by  the  proportion
f  patients  with  NYHA  functional  class  I or  II at  6-month
ollow-up.
The  main  limitation  of  our  study  was  the  signiﬁcant
mount  of  missing  data  corresponding  to  variables  not
ir  procedure  and  at  6-month  follow-upa.
Cases  with  matched  data  (n)  P
ostprocedure
16  1
12  0.51
12  0.58
12  0.032
r; LVESD: left ventricular end-systolic diameter; PAPs: systolic
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[Percutaneous  mitral  valve  repair  with  MitraClip  
reported  from  each  centre;  this  is  the  reason  why  our  tables
indicate  the  number  of  cases  with  matched  data  for  greater
clarity.  Mid-term  follow-up  data  (at  6  months)  on  efﬁcacy
and  tolerance  were  only  available  for  a  limited  number  of
patients.  Finally,  a  long-term  view  is  needed  to  accurately
determine  the  beneﬁt  of  the  MitraClip  procedure  on  func-
tional  status.
It  is  too  early  to  deﬁne  who  would  be  the  best  candidates
for  this  technique,  although  the  recent  recommendations
of  the  European  Society  of  Cardiology/European  Associa-
tion  for  Cardio-Thoracic  Surgery  have  mentioned  this  option
for  the  ﬁrst  time.  Percutaneous  MVR  may  be  considered
in  patients  with  symptomatic  severe  primary  MR  who  ful-
ﬁl  the  echo  criteria  of  eligibility,  are  judged  inoperable
or  at  high  surgical  risk  by  a  heart  team  and  have  a life
expectancy  >  1  year  (recommendation  class  IIb,  level  of  evi-
dence  C)  [11].  This  option  may  also  be  considered  in  patients
with  symptomatic  severe  secondary  MR  despite  optimal
medical  therapy  (including  cardiac  resynchronization  ther-
apy  if  indicated),  with  the  same  criteria  as  for  primary  MR
(recommendation  class  IIb,  level  of  evidence  C)  [11,12].
As  the  level  of  evidence  supporting  its  routine  use  in
patients  with  secondary  MR  is  limited  to  cohort  studies,
prospective  comparative  studies  are  now  mandatory  in  order
to  assess  the  impact  of  percutaneous  MVR  in  terms  of  cardio-
vascular  mortality  and  morbidity,  as  well  as  quality  of  life.
The  COAPT  and  RESHAPE  trials  have  recently  started  in  well-
deﬁned  populations  of  patients  with  secondary  MR  [13,14].
Furthermore,  the  cost  of  this  new  therapeutic  approach  is
currently  not  reimbursed  in  France,  limiting  its  diffusion  on
a  larger  scale.  Therefore,  considering  the  potential  impact
of  the  percutaneous  correction  of  severe  MR  in  terms  of
reducing  the  rate  of  unplanned  hospitalizations,  evaluation
should  include  both  clinical  and  economical  endpoints,  i.e.
the  ‘cost-effectiveness  ratio’  of  this  technique  vs.  optimal
medical  treatment.  A  French  multicentre  randomized  trial
—  the  MITRA-FR  study  —  has  just  been  approved  by  the  ‘Pro-
gramme  Hospitalier  de  Recherche  Clinique’  (French  Health
Ministry)  and  will  soon  be  underway  in  patients  with  severe
symptomatic  secondary  MR.
Conclusions
In  conclusion,  due  to  promising  results,  the  success  of
the  MitraClip  is  growing,  with  more  than  6000  patients
implanted  worldwide,  particularly  in  Northern  Europe  and
Italy.  The  preliminary  data  of  our  registry  are  encourag-
ing  in  terms  of  both  efﬁcacy  and  safety  and  may  solve
an  unmet  need  in  patients  who  are  ineligible  for  conven-
tional  surgery.  A  randomized  trial  has  been  approved  by
the  French  Health  Ministry  in  patients  with  cardiac  fail-
ure  and  secondary  MR  in  order  to  conﬁrm  these  results
with  a  higher  level  of  evidence,  leading  to  the  possibility
of  reimbursement  and  more  widespread  use  in  our  coun-
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